Affimed N.V EBITDA margin
What is the EBITDA margin of Affimed N.V?
The EBITDA margin of Affimed N.V. is -157.57%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on NASDAQ compared to Affimed N.V
What does Affimed N.V do?
affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli
Companies with ebitda margin similar to Affimed N.V
- MJardin has EBITDA margin of -159.16%
- Crown International has EBITDA margin of -159.07%
- Vivos Therapeutics has EBITDA margin of -158.97%
- Matador Mining has EBITDA margin of -158.68%
- Parx Materials N.V has EBITDA margin of -158.29%
- Pacific Biosciences of California Inc has EBITDA margin of -157.96%
- Affimed N.V has EBITDA margin of -157.57%
- Avacta Plc has EBITDA margin of -157.34%
- Sinopharm Tech has EBITDA margin of -157.13%
- SIMEC Atlantis has EBITDA margin of -157.03%
- Haydale Graphene Industries plc has EBITDA margin of -156.92%
- China Yanyuan Yuhui Natl Ed Grp has EBITDA margin of -156.64%
- Gbs Software Ag Konv has EBITDA margin of -156.33%